Neuropathology Core

恶性神经胶质瘤被认为是人类最致命的癌症之一。虽然我们已经获得了 详细了解神经胶质瘤中突变的一些遗传途径，最近的研究表明， 突变在该疾病的表型和抗性中起重要作用。的总体目标 神经病理学核心是提供专家，高通量，高度集成的组织为基础的分析， 人和小鼠胶质瘤P01。每一个项目的研究都在很大程度上基于体外生物学。 人类和小鼠胶质瘤，因此，神经病理学核心服务是成功的关键 关于P01此外，核心努力通过开发 新兴的组织技术，将减少每个项目在研究中遇到的困难， 有限的组织资源。此外，核心的集中性质将促进知识资源共享 并允许研究人员在所进行的研究范围内比较和解释他们的发现 在所有的项目中。神经病理学核心有三个具体目标：1）提供病理分析 以及对人类和小鼠胶质瘤的解释。2)来表征人类和小鼠胶质瘤， 分子病理学工具。3)开发和实施新技术， 人和小鼠神经胶质瘤的表征。核心有必要的神经病理学专业知识 先进的资源和经验丰富的工作人员来实现这些目标，并确保P01符合其 发现恶性胶质瘤治疗靶点的总体目标。

Malignant gliomas are considered to be among the deadliest of human cancers. Although we have gained detailed knowledge of a number of genetic pathways mutated in gliomas, recent studies suggest additional mutations play significant role in the phenotype and resistance of this disease. The overall goal of the Neuropathology Core is to provide expert, high throughput, and highly integrated tissue based analysis of human and mouse gliomas the P01. The research of each project is heavily based upon the in vtvo biology of human and mouse gliomas, and as such, the Neuropathology Core services are essential for the success of the P01. In addition, the Core strives to improve the services it delivers through the development of emerging tissue technologies that will reduce the difficulties each project encounters in studying increasingly limited tissue resources. Moreover, the centralized nature of the Core will foster intellectual resource sharing and allow investigators to compare and interpret their findings within the spectrum of research performed across all the projects. The Neuropathology Core has three specific aims: 1) to provide pathologic analysis and interpretation of human and mouse gliomas. 2) to characterize human and mouse gliomas using molecular pathology tools. 3) to develop and implement novel technologies for cellular and molecular characterization of human and mouse gliomas. The Core has the requisite neuropathologic expertise, sophisticated resources, and experienced staff to carry out these aims and ensure that the P01 meets its overall goals of discovery of targets for therapy in malignant glioma.